Mimic human complexity in a beat!
At BiomimX® we develop clinically relevant and fast responsive technology driven solutions tailored made to fit applications in Big Diseases.
Integrating 3D cell culture and mechanical stimulation, BiomimX® proposes the next generation of beating organs-on-chips, allowing to recapitulate human organs’ function and human diseased states with an unprecedented level of precision.
BiomimX® is a technology driven company projected towards the development of innovative and 3R compliant preclinical solutions that will revolutionize the standards for testing drug and medical devices.
Our innovative technology combines mechanical stimulation and 3D architecture with the advantages of the microscaled systems.
uBeat® Platform to culture, uCase to organize, uBox to stimulate.
Drug cardiotoxicity, Drug and Medical Device efficacy and much more. Towards personalized medicine applications.
If you want to explore our uBeat® based in vitro pre-clinical models and services, contact our partners at Bio-Digital 2021:
ONCOBONE Ltd will deepen the potential of uKnee, the first in vitro osteoarthritic human model for drug and intra-articular medical device screening;
M‑Squared Consulting SrL will illustrate the capability of uHeart to trigger the pathophysiological states of human myocardium for drug screening.
DRUG DISCOVERY AND SAFETY
BiomimX® provides advanced human in vitro models to detect drug efficacy and adverse effects, representing a more clinically relevant alternative to existing models.
MEDICAL DEVICE ASSESSMENT
In line with the new EU Medical Device Regulation (MDR (EU)2017/745), BiomimX® offers advanced preclinical models to test medical device efficacy before undergoing clinical trials.
Future developments include envisioned precision medicine approaches, where candidate compounds and therapies are screened on disease- and, ultimately, patient-specific models.